Valuation -- 6/10
MO trades at a substantial discount to Philip Morris (~11.7x vs. ~18.7x forward P/E), which is
justified by PM having a far superior smoke-free growth engine (IQOS, ZYN). However, MO is not
expensive vs. BTI or Japan Tobacco even though it has better US pricing power and a cleaner
balance sheet. The forward P/E implies the market prices in minimal growth beyond cigarette cash
flows. Any improvement in smoke-free execution or multiple expansion toward even 13x would imply
meaningful upside (~$72-$74). The 6.45% dividend yield provides a meaningful floor, but the catalysts
needed to move the stock higher require regulatory cooperation and competitive wins in smoke-free
that remain uncertain.
Weight: 15%
Forward P/E (2026E)
11.7x
vs PM ~18.7x, BTI ~12x
Trailing P/E
16.0x
vs PM ~21.8x, BTI ~13x
Dividend Yield
6.45%
60th consecutive annual increase
Debt / EBITDA
2.0x
At target leverage; clean balance sheet
Peer valuation comparison
| Company | Market Cap | Fwd P/E | Trailing P/E | EV/EBITDA | Div Yield | Debt/EBITDA | Beta |
|---|---|---|---|---|---|---|---|
| Altria (MO) | $109.9B | 11.7x | 16.0x | ~9.5x | 6.45% | 2.0x | 0.45 |
| Philip Morris (PM) | -- | ~18.7x | ~21.8x | ~15x | ~3.4% | ~2.3x | 0.65 |
| British American (BTI) | -- | ~12x | ~13x | ~8.5x | ~7.0% | ~2.8x | 0.55 |
| Japan Tobacco (JAPAY) | -- | ~11x | ~12x | ~8x | ~4.5% | ~2.5x | 0.50 |
| Key Takeaway | MO trades at a deep discount to PM, roughly in-line with BTI/JAPAY. Discount is justified by PM having superior smoke-free growth (IQOS, ZYN). MO has the cleanest balance sheet in the group and the highest-quality dividend streak (60 consecutive increases). | ||||||
Peer multiples are approximate and based on consensus estimates. MO data as of April 2026.
Data sourced from Daloopa and public filings.
Forward estimates and key fundamentals
| Metric | 2024Q1 | 2024Q2 | 2024Q3 | 2024Q4 | 2025Q1 | 2025Q2 | 2025Q3 | 2025Q4 |
|---|---|---|---|---|---|---|---|---|
| Net Revenue ($M) | $5,576 | $6,209 | $6,259 | $5,974 | $5,259 | $6,102 | $6,072 | $5,846 |
| Adj. Diluted EPS | $1.15 | $1.31 | $1.38 | $1.29 | $1.23 | $1.44 | $1.45 | $1.30 |
| Cig. Vol. (M sticks) | 16,450 | 17,898 | 17,641 | 16,593 | 14,204 | 16,066 | 16,192 | 15,290 |
| Adj. Cig. Vol. Decline (YoY) | -- | -11.0% | -11.5% | -11.0% | -- | -10.5% | -9.0% | -7.0% |
| Industry Vol. Decline (YoY) | -9.0% | -9.5% | -9.0% | -8.0% | -9.0% | -8.5% | -8.0% | -6.5% |
| Annualized Dividend | $3.92 | $3.92 | $4.08 | $4.08 | $4.08 | $4.08 | $4.24 | $4.24 |
| Consol. EBITDA ($M, TTM) | $12,032 | $12,136 | $12,045 | $12,157 | $12,305 | $12,538 | $12,605 | $12,593 |
Cigarette volume declines are moderating (from -11% to -7% adjusted). EBITDA is stable to slightly growing.
Smokable OCI margins expanded to 63.4% for FY2025. 2026E EPS guidance: $5.56-$5.72 (+2.5% to +5.5% vs. $5.42 base).
Data sourced from Daloopa and public filings.
Key catalysts (2026-2027)
| # | Catalyst | Timeline | Magnitude | Probability |
|---|---|---|---|---|
| 1 | ON! PLUS national rollout | H1 2026 | Medium | High (80%) |
| National retail launch began March 2026. FDA-authorized in Mint, Wintergreen, Tobacco. Early consumer feedback positive. 6 additional flavor PMTAs filed Nov 2025. Key question: can it take meaningful share from ZYN? | ||||
| 2 | Illicit e-vapor enforcement | 2026+ | High | Medium (50%) |
| $200M FDA enforcement budget mandated. Tariffs on Chinese imports adding friction. If illicit disposables (~70% of e-vapor) are curtailed, cigarette volume declines could moderate to -4% to -5%. Management noted "early signs" of impact in Q4 2025. | ||||
| 3 | Double duty drawback / KT&G partnership | H2 2026 | Medium | High (75%) |
| Import-export program unlocks federal excise tax recovery. Payback < 1 year per CFO. CapEx guide elevated to $300M-$375M. Opens door to future international cigarette production opportunities. | ||||
| 4 | Cigarette volume decline moderation | 2026 | Medium-High | Medium (55%) |
| Q4 2025 adjusted industry decline of -6.5% was best in 2 years (vs. -9.5% in Q2 2024). Management revised cross-category impact estimate down to 2-3% from 3-4%. Sustained moderation toward -5% would be very supportive of OCI growth. | ||||
| 5 | Dividend growth + buybacks | Ongoing | Low-Medium | Very High (95%) |
| $4.24 annualized dividend (6.45% yield). $1B remaining under $2B buyback program expiring Dec 2026. 60th consecutive annual increase. Provides meaningful downside floor. | ||||
| 6 | FDA Ploom / Marlboro heated tobacco PMTA | 2027+ | High | Low-Medium (30%) |
| Horizon filed combined PMTA+MRTPA application in Aug 2025. FDA approval would give MO a US heated tobacco product under the Marlboro brand -- transformative but timeline is long and uncertain. | ||||
| 7 | Multiple re-rating | 12-18 months | High | Low-Medium (30%) |
| If MO demonstrates credible smoke-free growth (ON! PLUS share gains, Ploom pathway, NJOY pipeline), the discount to PM could narrow. Even 1-2x of P/E expansion from 11.7x to 13.5x would imply ~$75-$77. ESG exclusion lists remain a headwind. | ||||
Key risks (bear case)
| # | Risk | Severity | Probability | Detail |
|---|---|---|---|---|
| 1 | Accelerating cigarette volume decline | HIGH | Medium (40%) | Industry decline rates have improved from -9.5% to -6.5%, but any reversal (economic downturn driving e-vapor adoption, new competition) would pressure OCI growth. Pricing power of ~8% net realization provides buffer but has limits. |
| 2 | NJOY franchise effectively impaired | MEDIUM | High (70%) | NJOY ACE pulled from US market March 2025 due to ITC patent ruling (JUUL IP). Management guides ACE will NOT return in 2026. $1.3B impairment taken in Q4 2025. E-vapor revenue only $21M in Q4 2025. |
| 3 | ON! PLUS fails vs. ZYN | MED-HIGH | Medium (45%) | ZYN shipped 794M US cans in 2025 with 37% growth. ON! shipped 177M cans (11% growth). PM has massive scale advantage. Category prices down 12% YoY while ON! raised prices 3%. |
| 4 | Illicit market persists / enforcement fails | MEDIUM | Medium-High (55%) | Illicit e-vapor is ~70% of category (~86% of retail sales). $4.1B in Chinese vape exports to US in 2025 (+11% YoY). Even with $200M FDA budget, enforcement is logistically challenging. |
| 5 | Marlboro share erosion / discount pressure | MEDIUM | Medium (50%) | Marlboro retail share dropped below 40% for first time in Q4 2025. Discount segment grew 2.2 share points in FY2025. Consumer economic pressures are the primary driver. |
| 6 | ESG / institutional exclusion | LOW-MED | High (80%) | Many institutional investors and index funds exclude tobacco. Creates a persistent valuation discount that limits re-rating potential regardless of fundamentals. |
| 7 | Menthol ban returns (future admin) | VERY HIGH | Low (15%) | Trump FDA formally withdrew the proposed rule in Jan 2025. Menthol is ~35% of MO cigarette volumes. Risk is dormant but not eliminated -- could resurface post-2028 election cycle. |
| 8 | Tobacco litigation tail risk | HIGH | Low (20%) | Ongoing tobacco and health litigation. NPM adjustment items and potential new lawsuits remain background risk. Periodically creates headline risk. |
| 9 | Federal excise tax increase | HIGH | Low (10%) | Historically rare but periodically proposed. Unlikely under current administration but future administrations could pursue. Would directly reduce pricing power. |
| 10 | ABI stake concentration risk | LOW | Medium (35%) | 10% stake in AB InBev represents meaningful asset value. Any ABI-specific downturn creates mark-to-market risk and equity earnings volatility. |
Scenario analysis
| Scenario | 2026E EPS | Multiple | Implied Price | Return | Probability |
|---|---|---|---|---|---|
| Bull | $5.70 | 13.5x | ~$77 | +17% | 25% |
| ON! PLUS share gains, enforcement works, volume decline moderates to -5%, duty drawback ramps | |||||
| Base | $5.60 | 11.7x | ~$66 | 0% + 6.45% div | 50% |
| Guidance achieved at midpoint, modest ON! PLUS traction, illicit market persists | |||||
| Bear | $5.40 | 10.5x | ~$57 | -13% + 6.45% div | 25% |
| Volume decline re-accelerates, ON! PLUS disappoints, litigation headline | |||||
Probability-weighted return: ~+2% capital appreciation + 6.45% dividend = ~8.5% total return.
Current price: $65.76.
Bull and bear scenarios
Bull Case (~$77, 13.5x 2026E EPS)
- ON! PLUS gains meaningful share vs. ZYN with differentiated product and FDA authorization
- Illicit e-vapor enforcement works; cigarette volume declines moderate to -4% to -5%
- Duty drawback program ramps with <1 year payback, creating incremental earnings tailwind
- Multiple expands from 11.7x to 13.5x as smoke-free credibility improves
- 6.45% dividend yield + $1B buyback provide downside floor and shareholder returns
Bear Case (~$57, 10.5x 2026E EPS)
- Cigarette volume declines re-accelerate as illicit e-vapor market persists
- ON! PLUS fails to gain share; ZYN dominance is insurmountable at 794M vs. 177M cans
- NJOY e-vapor strategy remains impaired with no clear path to market for modified ACE
- Marlboro share continues eroding below 40% as discount segment grows
- Tobacco litigation headline or menthol ban discussion resurfaces
- ESG exclusion caps investor universe and prevents multiple re-rating
Score rationale
Score of **6/10** reflects a balanced but cautiously favorable risk/reward setup. The stock is priced for terminal decline, so anything that goes right (enforcement, ON! PLUS, duty drawback) provides upside. But the catalysts are incremental, not transformative. The dividend yield does heavy lifting.
**Why not higher (7-8):** NJOY ACE is effectively dead for 2026 ($1.3B impairment signals management acknowledges the setback). E-vapor strategy is in disarray -- JUUL patent litigation ongoing, illicit market dominates. ON! is a distant #2 to ZYN (177M vs. 794M cans) in a category with intense promotional warfare. EPS growth guidance of 2.5-5.5% is uninspiring and consensus sits at the low end. ESG exclusion limits the investor universe and caps re-rating potential. Marlboro share below 40% for the first time is a psychological and fundamental negative.
**Why not lower (4-5):** Menthol ban withdrawn -- the single largest regulatory overhang is removed for now. Cigarette volume declines are objectively moderating (Q4 2025 was -6.5% vs. -9.5% a year ago). Cheap valuation at 11.7x forward with 6.45% yield provides downside protection. ON! PLUS launch is a credible growth vehicle with FDA authorization and positive early feedback. Balance sheet is clean at 2.0x debt/EBITDA with $1B buyback remaining. Duty drawback program provides incremental earnings tailwind with <1 year payback.
**Net assessment:** The risk/reward is modestly positive. This is more right than wrong for income-oriented investors, but not a compelling growth or catalyst story. Probability-weighted total return of ~8.5% (2% capital + 6.45% dividend) is adequate but not asymmetrically compelling.
Data sourced from Daloopa, company earnings transcripts, and public consensus estimates. Analysis as of April 2026.